Abstract
To examine trends and variations in Medicare Advantage (MA) prior authorization (PA) policies across insurers, years, and selected high-cost infusion immunotherapies and biosimilars, including rituximab, pembrolizumab, nivolumab, trastuzumab, and bortezomib.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
